CA2249778A1 - Competitive apo-peroxidase assay - Google Patents
Competitive apo-peroxidase assay Download PDFInfo
- Publication number
- CA2249778A1 CA2249778A1 CA002249778A CA2249778A CA2249778A1 CA 2249778 A1 CA2249778 A1 CA 2249778A1 CA 002249778 A CA002249778 A CA 002249778A CA 2249778 A CA2249778 A CA 2249778A CA 2249778 A1 CA2249778 A1 CA 2249778A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- apo
- peroxidase
- conjugate
- test sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Abstract
Disclosed is an assay for an analyte in a fluid test sample such as urine which involves combining the fluid test sample with a reagent system comprising an apo-peroxidase, a redox dye, a hydroperoxide and a metal porpyhrin which is bound to an analyte/analyte specific binding partner which conjugate has a combined molecular weight of at least about 180 K
Daltons. When this conjugate interacts with analyte in the fluid test sample, a portion of the specific binding partner is dissociated from the conjugate thereby enabling the metal porpyhrin to reconstitute with the apo-peroxidase. The reconstituted peroxidase can interact with the hydroperoxide and redox dye to provide a colored response to analyte in the fluid test sample.
Daltons. When this conjugate interacts with analyte in the fluid test sample, a portion of the specific binding partner is dissociated from the conjugate thereby enabling the metal porpyhrin to reconstitute with the apo-peroxidase. The reconstituted peroxidase can interact with the hydroperoxide and redox dye to provide a colored response to analyte in the fluid test sample.
Description
CO~ lv~ APO-PEROXIDASE ASSAY
Backqround of the Invention Peroxidase is an enzyme that catalyzes the oxidation of various compounds, such as phenols and amines, by peroxides.
Various compounds are referred to as pseudoperoxidases because they behave in a manner similar to the peroxidase enzyme by liberating an electron from hydroperoxides to create an oxi-dant capable of accepting an electron from a donor species.
Accordingly, the pseudoperoxidases are enzyme like in that they catalyze, or otherwise participate in, reactions between peroxides or otherwise oxidizable compounds. The pseudoper-oxidases, which include hemoglobin and its derivatives, are collectively referred to as peroxidatively active substances.
For example, a peroxidatively active substance, such as hemo-globin and its derivatives, catalyzes the interaction between a hydroperoxide and an oxidizable dye. In such interactions, the peroxidatively active substance imitates the peroxidase enzyme and catalyzes or otherwise participates in an interac-tion between the oxidizable dye and the peroxide. The oxygen transferred from a peroxide to a peroxidatively active sub-stance creates an oxidant capable of accepting an electron from an oxidizable dye. The resulting interaction provides a detectable response, such as a color transition, wherein the intensity of the response is indicative of the presence or the concentration of the peroxidatively active substance. Suit-able oxidizable dyes for use in such an assay include benzidine; o-tolidine, 3,3'5,5;-tetraalkylbenzidine wherein the alkyl groups contain from one to six carbon atoms; 9-dianisidine; 2,7-diaminofluorene; bis-(N-ethyl-quinol-2-one)-azine; (N-methylbenzthiazol-2-one)~ ethyl-3-phenyl-5-methyl-triazol-2-one)-azine or a combination thereof. Useful hydrop-eroxides include cumene hydroperoxide; 5-butyl hydroperoxide;
diisopropylbenzene hydroperoxide; 1-hydroxycyclohexane-1-hydroperoxide; 2,5-dimethyl-hexane-2,5-dihydroperoxide; para-menthane hydroperoxide; 1,4-diisopropylbenzene hydroperoxide;
p-5-butyl-isopropylbenzene hydroperoxide; 2-(a-hydroperoxy-isopropyl)-6-isopropylnaphthalene; tetralin hydro-peroxide or a combination thereof.
In U.S. Patent 4,493,890 it is disclosed that glucose oxidase is a conjugated enzyme composed of an enzymatically inactive, high molecular weight protein component (apoenzyme) and FAD (a low molecular weight, nonproteinaceous prosthetic group). Unlike transition metal porpyhrins, the flavin ade-nine dinucleotide (FAD) portion of glucose oxidase does not contain a transition metal. The FAD moiety is sometimes re-ferred to as a prosthetic group because the protein portion of the enzyme forms a complex with this small ligand through high affinity binding. As a result, the prosthetic group becomes an integral part of the protein which is required for the en-zyme to function. Apoglucose oxidase and FAD have a high binding affinity (binding constant of about 101~ molar -1) but can be effectively separated by treatment with acidified ammo-nium sulfate. In U.S. Patent 4,238,565 there is described a specific binding assay wherein FAD is employed as a label and is monitored by its ability to combine with apoglucose oxidase to form active glucose oxidase. In a homogenous assay for de-termining an antigen in a liquid medium, a test sample of the liquid medium is combined with antibody to the antigen and a labeled conjugate comprising the antigen (or analog thereof) coupled to FAD so that antigen contained in the sample com-petes with antigen-FAD for binding with antibody. Apoglucose oxidase is also present and is capable of combining with anti-gen-FAD which is not associated with antibody to yield active glucose oxidase. However, since antibody bound antigen-FAD is not capable of such combination with apoglucose oxidase, the concentration of antigen in the test sample dictates the amount of measurable glucose oxidase which results from the recombination by known methods such as a colorimetric assay.
This sort of assay, sometimes referred to as apoenzyme reacti-vation immunoassay system (ARIS) involves attachment of hapten to the FAD prosthetic group of glucose oxidase which still permits reactivation of the apoglucose oxidase by its interac-tion with the prosthetic group. However, binding of the anti-hapten antibody to the hapten-FAD conjugate can prevent its association with the apo-glucose oxidase, so that no glucose oxidase activity is observed. Glucose oxidase has been found to be an excellent enzyme for this system since i) the FAD can be dissociated from the intact enzyme to provide a stable apo-glucose oxidase, ii) the apoglucose oxidase cannot express en-zyme activity but can be easily reconstituted with FAD to the holoenzyme and iii) the parent holoenzyme has a high turnover rate and the H202 reaction product can be determined with high sensitivity by a variety of methods. However, the apoglucose oxidase ARIS method has not been successfully applied in uri-nalysis due to the presence of FAD derivatives in urine re-sulting in reconstitution with the apoglucose oxidase to form the active enzyme which can cause false positive assay re-sults. The ARIS systems are not limited by molecular weight .
of the prosthetic-conjugate:binding partner, i.e. reconstitu-tion occurs regardless of the molecular weight of the binding system. This type of assay is based on binding partner inter-action with the prosthetic-conjugate occurring in such an ori-entation that it causes steric hindrance to reconstitution.
This steric hindrance leads to an inhibition that causes the rates of reconstitution to be different between prosthetic conjugate and prosthetic-conjugate binding partner. The dif-ference in reconstitution rates of the two species is used to measure the analyte. Peroxidases also contain a prosthetic group in the form of a transition metal porphyrin which can be separated from the protein to form an apo-peroxidase. The apo-peroxidase system of the present invention is limited by the molecular weight of the analyte/analyte specific binding partner conjugate attached to the metal porphyrin since it was discovered that when this moiety has a total molecular weight of greater than that which will permit the apo-peroxidase and metal porphyrin to recombine, reconstitution with the peroxi-dase is prevented. Conjugates with a combined molecular weight of greater than about 180 K Dalton have been found to be suitable for preventing reconstitution. The present assay is based on the binding partner:prosthetic conjugate being so large that it prevents reconstitution. Since the binding partner typically has a high molecular weight (antibodies are normally in the 165 K Dalton range) the presence of peroxidase activity can only result from one species, the unbound pros-thetic-conjugate, and the activity of this single species is used to measure the analyte.
Steric hindrance to reconstitution requires a specific orientation of the antibody:antigen binding, which orientation is easily developed for small antigens but not for large anti-gens. Accordingly, the ARIS method is normally limited to small molecular weight antigens of 100 to 1000 g/mol. The present method does not rely on steric hindrance but rather on the molecular weight of the prosthetic-conjugate: binding partner. This technique results in the advantage that the as-say is able to detect any size of analyte and eliminates the need to prepare antibodies with a specific binding orienta-tion. Additionally, the present invention, which is based upon the discovery that the size effect can be used to provide an apo-peroxidase system, can be used without measuring rates.
This is especially advantageous in urinalysis using test strips since urine strips are usually read visually and visual readings are not readily applicable to rate determination.
The pseudoperoxidases also have prosthetic groups which, when removed, result in an inactive apo- form of the pseudop-eroxidase which lacks the peroxidase activity. For example, when iron hematin is separated from hemoglobin, such as by subjecting the hemoglobin to low pH to dissociate the iron hematin followed by filtration to cause the separation of the hematin and apo-hemoglobin, there is provided an inactive form of hemoglobin which may be reactivated by facilitating the re-constitution of the apo-hemoglobin and the iron hematin. The transition metals which constitute part of the metal porhyhrin will have a mixture of valences in reagents of the type under consideration.
In Abstracts of the Histochemical Society (1979), Item 39 on page 717 there is discussed an immunoassay using the degree of reconstitution of apoenzymes with active groups in the presence or absence of immuno complexes such as heme-labeled antigen when complexed with antibody will be inhibited from reconstituting with apoperoxidase.
Japanese published patent application 8-224095 discloses an assay system for Cu in which Cu is added to apogalactose oxidase in the presence of D-galactose and ~2 to produce H2O2 which reacts with an oxidative condensing agent in the pres-ence of peroxidase to produce a quinoid dye which colorimetri-cally measures the copper concentration in the fluid sample being tested.
While the use of the heme moiety as a label for apo-peroxidase was theorized by P. K. Nakanein, Univ. of Colo., Abstracts of the Histochemical Society, 39 (1979) where it was suggested that conjugated hematin-antigen would not readily intercalcate into apo-peroxidase when the antigen was bound to its corresponding antibody, an assay for analytes in fluid test samples employing this principle was never reduced to practice.
Summary of the Invention The present invention is an assay for an analyte in a fluid test sample which assay involves combining the fluid test sample with a hydroperoxide, a redox dye, an apo-peroxidase [or pseudo apo-peroxidase] and its corresponding metal porpyhrin which is bound to an analyte/analyte specific binding partner conjugate which conjugate has a total molecu-lar weight which is sufficiently high to prevent the porpyhrin component thereof from recombining with the apo-peroxidase.
, In this form the apo-peroxidase cannot interact with the hy-droperoxide to cause a colored response in the redox dye.
However, in the presence of analyte, there is interaction be-tween the analyte and the analyte specific binding partner which disrupts the analyte/analyte specific binding partner conjugate and thereby reduces the molecular weight of the moi-ety bound to the metal porpyhrin to less than that level at which the reconstitution of the apo-peroxidase and its pros-thetic group is inhibited. This allows the apo-peroxidase and the metal propyhrin to reconstitute to form an active peroxi-dase which can interact with the hydroperoxide and the redox dye to provide a colored response, the intensity of which is directly proportional to the concentration of analyte in the fluid test sample.
The assay of this invention can be used qualitatively or, with the use of appropriate calibration, colorimetric dyes and instrumentation to provide accuracy and precision, semi-quantitative results can be obtained.
Description of the Invention Metal-porpyhrins are the active center of peroxidatively active proteins and their removal such as by acidification and separation by either ultrafiltration or chromatography results in the formation of apo-peroxidases which have no peroxidase activity but which can be reactivated when mixed with metal-porphrins, even those which are conjugated to antigens. How-ever, antibody binding to these antigen/metal-porphyrin conju-gates prevents reactivation of the apo-peroxidase when this combination exceeds about 180 K Daltons in molecular weight.
Free antigen (analyte) in a fluid test sample, to which the antibody bound to the antigen of the antigen/metal porphyrin conjugate has been added, competes for antibody binding thereby freeing the antigen/metal porpyhrin conjugate from the antibody in proportion to the analyte present in the fluid test sample. In the case of antigen/metal porpyhrin conju-gates having a total molecular weight of less than about 180 K
Daltons, the antibody free conjugate reactivates the apo-peroxidase to the active form. The activity of the reacti-vated peroxidase can be detected using a redox indicator and a hydroperoxide at a pH of from 1 to 12 and preferably from 6.5 to 8.5. In this embodiment of the invention, there is pro-vided a test composition comprising:
i) a redox indicator and a peroxide as well as a buffer to maintain the pH at the optimal value, depending upon the metal and redox indicator used, of from 1 to 12;
ii) the specific binding partner (analyte or binding partner therefor)/metal-porpyhrin conjugate;
iii) the peroxidatively active substance lacking a pros-thetic heme group, i.e. apo-peroxidase; and iv) conjugate binding compounds.
The conjugate binder can take one of two forms:
a) if an antibody is bound to the metal porpyhrin, the binder is the antigen or the antigen bound to a larger molecule such as a protein, or b) if an antigen is bound to the conjugate, the binder can be an antibody or an antibody connected to a larger molecule or other biomolecules that bind the antigen can be used. For example, when LPS is the antigen, high density lipoprotein (HDL), which binds LPS, can be used. In the case where IgG is the ana-lyte, the binding partner can be complement factor protein.
Exemplary of antigen/metal-porpyhrin conjugates are met-als such as Fe, Mn, Cu and Co; porphyrins such as hematin, deteroporphyrin and coproporhrin and antigens such as pro-teins, low molecular weight organics and cell wall components.
Examples of apo-peroxidases and pseudoperoxidases which may be used in the present invention are apo-peroxidase, apo-hemoglobin, apo-myoglobin, apo-cyochrome-C, apo-catalyase and apo-lactoperoxidase.
This invention involves a dry reagent involving a new colorimetric technology based on a competitive apo-peroxidase chemistry which is useful for measuring small and large mo-lecular weight components in biological fluids such as blood and urine. Typical analytes involve drugs, proteins and cells, i.e. gram positive and gram negative bacterial cells.
The invention is based on the discovery that metal-porpyhrin conjugates will not intercalcate into apo-peroxidases when bound by a conjugate binder as long as the conjugate:binder complex has a molecular weight of greater than about 180,000 g/mol. It was found that conjugation of compounds up to a mo-lecular weight of an antibody (160,000 g/mol) did not inter-fere with apo-peroxidase reactivation, so that the conju-gate:binder complex can be an antigen:antibody complex wherein the antigen is the analyte whose presence or concentration is being sought and the antibody is a specific binding partner for the analyte. Specific binding partners other than anti-bodies include avidin/biotin pairs. The metal porpyhrin con-jugate can, for example, be comprised of an antibody and metal hematin wherein the conjugate binder (ligand) would be an an-tigen which is the analyte or derivative thereof recognized by the antibody and the analyte is the antigen recognized by the antibody. When the antibody antigen combination has a com-bined molecular weight of greater than about 180 K daltons it cannot intercalcate with the apo-peroxidase and a peroxidase catalyzed reaction does not result. However, when the conju-gate, conjugate binder, apo-peroxidase and a hydroperoxide are combined with a fluid test sample containing analyte, there takes place a competitive reaction in which analyte in the sample competes for binding with the antibody bound to antigen on the conjugate, and, to the extent that this competition strips antibody from the conjugate, thereby lowering its mo-lecular weight to below about 180 K Daltons, the conjugate can combine with the apo-peroxidase to provide an active enzyme which will catalyze the reaction needed to provide the detect-able response. The magnitude of this response will be propor-tional to the concentration of analyte in the test fluid which concentration can be determined by comparison with calibration charts prepared using known concentrations of analyte. A
similar response will be observed when the metal porhyhrin is conjugated with an antibody specific for the antigen (analyte) and the binder is the analyte or analyte derivative.
The method of practicing the present invention is further illustrated by the following procedures and examples.
A. Procedure for Preparing Reagent Used in Examples IV to VII.
Dry reagent paper was prepared through sequential impreg-nations of Whatman 3MM with an aqueous first dip and an etha-nol second dip using dryer temperatures of 100~C for 7 min-utes. The first dip contained buffer while the second dip contained the redox indicator, TMB, and the hydroperoxide, DBDH.
The first dip consisted of 10 mL of 73 mg/dL hematin-IgG, 1.0 mL of 10 mg/mL mouse anti-human kappa chain monoclonal an-tibody, 0.66 g glycerol-2-phos-phate, 4.2 ~M apo-hemoglobin, 0.63 g 4-morpholine propane sulfonic acid (MOPS) as buffer and 0.11 g of sodium dodecyl sulfate (SDS) as surfactant. The pH
was adjusted to 7.5 with IN NaOH.
The second dip contained 2.5 g of polyvinylpyrolidone, 1.6 g DBDH and 0.795 g TMB in 100 mL ethanol.
The preferred concentration and allowable range of each dip component are set out in Table 1:
APO-PEROXIDASE REAGENT
Preferred Allowable Concentration Range First Dip (aqueous) Glycerol-2-Phosphate225 nM 0-800 mM
MOPS 225 mM 0-800 mM
SDS 28 mM 8-100 mM
Fe-HEDTA (ascorbate 7.5 mM 0-20 mM
scavenger) Triisopropylamine borate 33 0-120 (stabilizer) Fe Hematin-antigen (metal 3.2 ~M 1-20 ~M
porpyhrin conjugate) Ab (competitive binder) 4.4 ~M 1-20 ~M
Apo-hemoglobin (Apo-peroxidase) 4.2 ~M 1-20 ~M
Adjust pH with 1 N NaOH 7.5 1-12 Second Dip (ethanol) Polyvinylpyrrolidone 2.5 w% 0-7.5 w%
Tetramethylbenzidine (TMB) 33 mM 5-100 mM
Diisopropyl benzene dihydroperoxide (DBDH) 66 mM 5-150 mM
Orange G dye (Background dye) 0.20 mM 0-5 mM
Ethyl Orange dye (Background 0.20 mM 0-5 mM
dye) B. The reagent papers produced from the above dips were cut into strips and dipped into urine containing various hematins from a urine pool of 1.015 specific gravity. The reflectance at 660 nm, measured using a CLINITEK -200+ instrument, ob-tained one minute after dipping, was taken as representative of reagent activity.
Example I - Detection Limit Study In this example apo-peroxidase is compared to hematin and hematin-antigen conjugates to determine the detectable concen-trations and effects of conjugation and antigen molecular weight on apo-enzyme reactivations. Solutions containing com-binations of apo-POD, Fe 3 hematin and hematin conjugate were tested for peroxidase activity. Peroxidase activity was meas-ured in urine using HEMASTIX~ reagent as set out in Table 3.
This reagent is similar to that set out in Table 1 but lacking the metal porphyrin conjugate, competitive binder and apo-peroxidase while containing lepidine as an activator. The re-sults of this detection limit study are set out in Table 2.
Mean ~ Reflectance @ 660 nm (1 minute @ 30~ C) Case Composition Conc: 3.6 mM 3.6 nM 3.6 nM
A hematin 65.1 64.9 63.4 C apo-POD, hematin 55.3 46.3 48.9 E apo-POD 64.1 62.3 61.2 antigen: 8JP IgG Sulf-methazine M~l~rlll~r Wt. 23,000 160,000 278 P Antigen-hematin 65.8 67.0 64.5 D apo-POD, antigen-hematin 49.1 39.9 42.3 The peroxidase activity of hematin (Case A) or antigen hematin conjugate (Case B) was not detectable at a concentra-tion of 3.6 nM. The apo-POD also demonstrated no activity by itself (Case E) whereas the peroxidase activity of hematin (Case C) and antigen-hematin conjugate (Case D) was detectable at 3.6 nM in the presence of apo-POD. This example demon-strates that detection of nM quantities via peroxidase reacti-vation is possible with the redox indicator and hydroperoxide technology which has a turn over rate of 10 moles of DBDH/min and a dye (TMB) molar extinction of 10 . Conjugation of the hematin with antigen did not interfere with the apo-enzyme re-activation. In fact, in the antigen hematin conjugates of Case D, the reactivation caused a response as great as 25.0%R
at 1 minute, as can be determined by comparing 3.6 nM apo-peroxidase (Case E) to 3.6 nM apo-peroxidase:antigen-hematin (Case D). Surprisingly, conjugation of antigens up to a mo-lecular weight of 160,000 g/mol (in the case of IgG) did not prevent reactivation of the apo-POD. Reactivation was com-plete in 1 minute (demonstrating the short equilibrium times) and was not dependent upon temperatures from 20-40~C or apo-POD concentration.
Procedure for Detection Limit Experiment A 10 ~L portion of hematin (3.6 ~M, 0.23 mg/dL in phos-phate buffered saline) or a 10 ~L hematin-BJP allotment (3.6 ~M, 8.61 mg/dL in phosphate buffered saline) was mixed with 10 ~L apo-POD (3.6 ~M, 14.0 mg/dL in phosphate buffered saline) all in 980 ~L of phosphate buffered saline and then diluted to the desired concentration with additional phosphate buffered saline. The solution was incubated for 1 minute at 40~C or at room temperature. The response of HEMASTIX~ reagent dipped into the test solution was measured on a CLINITEK -200 reflec-tance instrument. The response of the reagent set out in Ta-ble 1 on the phosphate buffered solution alone was 65.2% re-flectance at 1 minute.
Apo-horse radish peroxidase was obtained from Sigma Chemical Company of St. Louis, MO. The phosphate buffered so-lution was prepared by adding 0.69 g monobasic sodium phos-phate, 0.71 g of dibasic sodium phosphate and 0.45 g of sodium chloride to 100 mL of water.
Procedure for Antigen Response Experiment A 10 ~L sample of hematin-BJP (3.6 ~M, 8.61 mg/dL in phosphate buffered saline), anti-BJP (3.6 ~M, 52.56 mg/dL in PBS) and BJP (3.6 ~M, 8.28 mg/dL in phosphate buffered saline) were mixed with 10 ~L apo-POD (3.6 ~M, 14.0 mg/dL in phosphate buffered saline) and 960 L phosphate buffered saline. The so-lution was incubated for 5 to 10 minutes at room temperature and the response to HEMASTIX~ reagent dipped in the test solu-tion was measured using a CLINITEK~-200 instrument. The re-sponse of HEMASTIX~ reagent with the phosphate buffered saline solution containing hematin alone was 65.7% reflectance at 1 minute. Sheep anti-human BJP monoclonal antibody was obtained from The Binding Site Limited of Birmingham, England.
The HEMASTIX~ reagent referred to earlier with the addi-tion of lepidine and at a lower pH when compared to the for-mula of Table 1 was applied to the strip in a two dip system of the following composition and used in Examples I to IV.
BJP = Bence Jones Protein CA 02249778 l998-l0-08 Allowable First Dip (Aqueous)Concentration Range Glycerol-2-Phosphate225 mM 0-800 mM
MOP 225 mM 0-800 mM
SDS 28 mM 8-100 mM
Triisopropylamine borate 33 mM 0-120 mM
Fe-HEDTA 7.5 mM 0-20 mM
Adjust pH with 1 N NaOH 6.3 5.5-8.5 Second Dip (Ethanol) Polyvinylpyrrolidone2.5 w% 0-7.5 w%
Tetramethylbenzidine [TMB] 33 mM 5-100 mM
Diisopropyl Benzene Dyhydroperoxide [DBDH] 66 mM 5-150 mM
Lepidine 100 mM 5-150 mM
Orange G dye (background dye) 0.20 mM 0-5 mM
Ethyl Orange dye (background dye) 0.20 mM 0-5 mM
Example II - Proximity Effect In this example, antibody binding of the hematin-antigen conjugate is shown to prevent apo-enzyme reactivation (Table 3). The data set out in Table 3 were generated by using the HEMASTIX~ formula with lepidine but lacking apo-peroxidase, antigen-hematin antigen and antibody. The later were mixed in solution and reagent strips with the modified HEMASTIX~ for-mula were immediately dipped into the solution and read using a CLINITEKTM-200+ reflectance spectrometer.
The prevention of apo-enzyme reactivation was observed as long as the [hematin] antigen/antibody complex had a molecular weight of greater than 180,000 g/mol. Accordingly, sul-famethazine plus antibody (mol wt. # 161,000) did not prevent apo-enzyme reactivation. However, attachment of sulfmethazine to polyacrylic acid (PAA) (mw = 200,000 g/mol) did prevent re-activation of the apo-enzyme as shown by 51.5%R observed for run 10. It was also shown that an antigen (IgG-mol. wt.
160,000 and BJP-mol. wt. 23,000) could be detected in urine by its ability to free hematin-antigen[antibody] conjugate to re-activate apo-POD by breaking the binding between antigen and antibody.
APO- Antigen- Roagent Response (%R
Run Antigen Peroxidase Hematin [Antigen] Antibody @ 30 Sec) @ 660 nm 1 BJP 36 nM 36 nM None 36 nM 43.1 2 aJP 36 nM 36 nM 12 nM 36 nM 33.7 3 ~3JP 36 nM 36 nM 24 nM 36 nM 26.6 4 aJP None 36 nM 36 nM 36 nM 41.7 PJP 36 nM 36 nM None None 24.2 6 IgG 36 nM 36 nM None 36 nM 42.4 7 IgG 36 nM 36 nM 24 nM 36 nM 19.2 a Sulfamethazine 36 nM 36 nM None 36 nM 23.6 9 Sulfamethazine 36 nM 36 nM 24 nM 36 nM 21.3 Sulfmethezine 36 nM 36 nM None 36 nM 51.5 PAA
11 Sulfmethazine 36 nM 36 nM 24 nM 36 nM 49.2 PAA
Example III - Interference Study In this example, a peroxidase detecting dry reagent with resistance to 0.81 mg/dL hemoglobin (or myoglobin) and 25 mg/dL ascorbate and sufficient sensitivity to detect apo-peroxidase reactivation was used. The peroxidase detecting reagent was made by removing lepidine activator in the HE-MASTIX~ reagent and increasing the pH to 7.5. Without modifi-cation, hemoglobin (or myoglobin) causes a false positive re-sponse. Ascorbate does not cause a false negative response in the system due to the use of an ascorbate scavenger system.
The reagent was tested by dipping it into solutions con-taining the interfering substance with and without Fe hematin.
These formulation changes to the HEMASTIX~ reagent also re-duced the sensitivity of the reagent needed to detect apo-peroxidase reactivation from 3 nM in Example I to 12 yM in this Example III. As expected, the 12 yM hematin was acti-vated by the addition of 12 yM apo-POD. The results of this interference study are set out in the following Table 5.
0.81 mg/dL 0.81 mg/dL 25 mg/dL
Reagent Water Mb Hb Ascorbic Mean SD Mean SD Mean SD Mean SD
~IRMA!::'I'TY~
(lepidine/pH 6.3) 63.6 3.1 5.1 2.7 3.0 0.4 66.4 4.5 + 3.6 ~M Fe Hematin 8.8 1.9 + 12 ~M Fe Hematin 6.4 1.0 5.3 0.6 + 12 ~M Fe Hematin/ 4.1 0.4 12 ~M apo-POD
+ 36 ~M Fe Hematin 3.1 1.4 HEMAS~IX~
(no lepidine/pH 7.5) 77.4 1.7 78.2 1.6 76.5 1.2 79.4 2.3 + 3.6 ~M Fe Hematin 79.2 1.3 + 12 ~M Fe Hematin 72.4 3.0 73.2 3.1 + 12 ~M Fe Hematin/
12 ~M apo-POD 54.0 5.7 55.3 3.4 From Table 5 one can determine that HEMASTIX~ with lepidine is interfered with by hemoglobin or myoglobin as shown by 5.1%
and 3.0% responses verses 78.2 and 76.5.
Example IV - Metal Porphyrin Study:
In this example, other metal porphyrins were tested for their ability to reactivate different types of apo-peroxidases. Metals such as Fe, Cu, Mg, Zn, Ni, Mn, Co and Pd were complexed to hematin and added to the peroxidase detect-ing agent. Metals such as Mn, Fe, Cu and Co and porphyrins other than hematin, i.e. deteroporhyrin and coproporphyrin . .
were also shown to provide the desired response. This is il-lustrated in Table 6 by the combination of apo-peroxidase with iron and manganese porphyrin resulted in color formation (lower % R) as compared to water. An apo-pseudo-peroxidase, apo-hemoglobin, was shown to work in this experiment.
~R @ 90 ~econd read time on CLINITEK -200+
Water 12 ~M apo-POD 12 ~M apo-Hb Reagent Mean SD Mean SD Mean SD
HEMASTIX~ (no lepitine/pH 7.5)Column 1 Column 2 Column 3 + 12 ~M Fe Hematin 71.5 1.9 50.9 4.2 45.3 1.2 + 12 ~M Fe .u~Lu~uL~l.yLln 69.7 1.1 56.4 3.6 52.1 3.5 + 12 ~M Fe deteroporphyrin 72.2 3.1 56.1 5.2 49.2 2.3 + 120 ~M Mn deterophpyrin 66.4 3.2 48.2 4.3 -~
+ 120 ~M Co deteroporphyrin 71.5 2.2 74.1 1.4 ---- ----+ 120 ~M Mg deteroporphyrin 74.4 1.3 70.9 2.9 ---- ----+ 120 ~M Pb deteroporphyrin 72.1 1.9 73.4 1.9 ---- ----+ 120 ~M Ni deteroporphyrin 75.5 2.4 76.1 2.1 ---- ----+ 120 ~M Zn det~L U~UL ~ly L in 71.3 1.5 70.7 1.8 ---- ----+ 120 ~M Cu deterporphyrin 73.7 3.9 57.2 1.2 ---- ----The data of Table 6 demonstrate that no metal porphyrin is detected without apo-peroxidase or apo-hemoglobin as shown by the percent reflectance in Column 1 being 2 66%R. The ad-dition of either apo-peroxidase or apo-hemoglobin causes a colored response as shown by %R of ~ 56 in Columns 1 and 3.
The response is similar for three different porphryins. The use of Mn and Cu resulted in responses similar to those ob-tained for Fe as shown in Column 2. The other metals were not active in this system since the activity of the metal is de-pendent on the particular peroxide, pH and redox indicator used.
Example V - Complete Dry Reagent - for IgG
In this example, the ascorbate and hemoglobin resistant reagent for detecting peroxidase reactivity was combined with apo-hemoglobin; Fe hematin conjugated to human IgG and anti-human IgG into one reagent (Table 1). As demonstrated by Ta-ble 7, the complete reagent detected IgG in urine with good correlation between the concentration of IgG in the test solu-tion and the response recorded.
96R @ 90 sec read time on CLINITEK -200+
Reagent 0 ~M 12 IIM 24 ,uM 36 ~IM
IgG IgG IgG IgG
Mean SD Mean SD Mean SD Mean SD
Apo-peroxidase 61.2 3.5 55.3 1.2 49.5 3.4 42.3 4.6 Reagent contained 12 IIM Fe Elematin-IgG, 12 ,uM anti IgG and 12 IIM apo-l ~lnh1n Example VI - Complete Dry Reagent for Gram Negative Cells In this example, the ascorbate and hemoglobin resistant reagent for detecting peroxidase activity was combined with apo-hemoglobin; Fe hematin conjugated and an antibody specific to an anti-rabbit bacterial lipopolysaccharide (LPS) into one reagent. The Fe-hematin-LPS conjugate was made up of 16.3 LPS
molecules attached to oval albumin along with 5. 2 hematin molecules. As demonstrated by Table 8, the complete reagent detected bacterial cells in urine with three species of gram negative cells being detected. Since all gram negative cells have LPS on their surfaces, this technique provides a screen for gram negative urinary tract infections. A specimen con-taining gram negative cells would disrupt the binding of the LPS conjugate to antibody as the LPS of the gram negative cells binds to the antibody. The LPS conjugate is then free to reconstitute with apo-hemoglobin to form its active form to generate a detectable response.
96 R @ 650 nm and 90 Sec Road Time on CLINITEK 200+
Organism ~ 103 105 107 cells/ul Proteus mirabilis (ATCC 25933) 65.0 58.7 44.8 P ' -~ aeruginosa (ATCC 9027) 71.5 53.3 48.5 38.2 E coli (ATCC 8739) 66.0 60.2 49.9 The antibody was rabbit anti-E. coli LPS; catalog #YBDB30506R: Lot #G4520; neat antisera; Accurate Chemical &
Scientific Corporation of Westbury, NY.
The following experimental methods were used in the fore-going examples:
Procedure for Preparation of Conjugate A 868 ~M solution of hematin in 0.1 N NaOH (55 mg/dL, 633.51 g/mol) was added to a 858 ~M solution of 1,3-dicyclohexyl carbodiimide in acetonitrile (19.4 mg/dL, 226 g/mol) and stirred for five minutes at room temperature. A
solution containing 25 yM of the activated hematin and 12 ~M
antigen (either human kappa Bence Jones Protein (BJP) at 30 mg/dL or human gamma globulin (IgG) at 200 mg/dL) was made and stirred for an additional five minutes at room temperature.
The hematin-antigen conjugate was separated from the free an-tigen by centrifugation to dryness using an Amicon Ultra fil-tration membrane followed by several washings with deionized water. Hematin conjugate is more reluctant to pass through the membranes than IgG or BJP resulting in the conjugate being collected on the membrane. After the final washing, the hematin-antigen conjugate was dissolved in 175 mL of deionized ., water. The reaction was found to be greater than 64% complete by protein determination using the coomassie brilliant blue method and contained 128 mg of protein/4.3 ~M conjugate.
The coomassie brilliant blue method was performed by add-ing 30 ~L of sample to 1.5 mL of Bradford reagent (0.01 g coomassie brilliant blue, 10 mL 85% phosphoric acid, 5 mL
ethanol and 85 mL water) and measuring absorbance at 590 nm and comparing the absorbance to a standard curve of protein concentration.
Procedure for making apo-hemoqlobin A 0.7% solution of hemoglobin was lowered to pH 1.5 and the resulting solution was ultrafiltered through a 10 KDa cut-off membrane followed by several changes of water. Filtered material was reconstituted into water. The apo-hemoglobin passed through the filter while the dark Fe hematin and hemo-globin remained behind. The filtrate, 440 mL of which was collected, was found to contain 430 mg of protein (apo-hemoglobin) by assay or 23 ~M. The HEMASTIX~ result was + for this solution indicating that the amount of hemoglobin was low. The collected fraction which did not pass through the filter was dissolved in 75 mL of water and was found to con-tain 270 mg of protein by assay. It produced a HEMASTIX~ re-sult of +++++ indicating a high concentration of hemoglobin.
Backqround of the Invention Peroxidase is an enzyme that catalyzes the oxidation of various compounds, such as phenols and amines, by peroxides.
Various compounds are referred to as pseudoperoxidases because they behave in a manner similar to the peroxidase enzyme by liberating an electron from hydroperoxides to create an oxi-dant capable of accepting an electron from a donor species.
Accordingly, the pseudoperoxidases are enzyme like in that they catalyze, or otherwise participate in, reactions between peroxides or otherwise oxidizable compounds. The pseudoper-oxidases, which include hemoglobin and its derivatives, are collectively referred to as peroxidatively active substances.
For example, a peroxidatively active substance, such as hemo-globin and its derivatives, catalyzes the interaction between a hydroperoxide and an oxidizable dye. In such interactions, the peroxidatively active substance imitates the peroxidase enzyme and catalyzes or otherwise participates in an interac-tion between the oxidizable dye and the peroxide. The oxygen transferred from a peroxide to a peroxidatively active sub-stance creates an oxidant capable of accepting an electron from an oxidizable dye. The resulting interaction provides a detectable response, such as a color transition, wherein the intensity of the response is indicative of the presence or the concentration of the peroxidatively active substance. Suit-able oxidizable dyes for use in such an assay include benzidine; o-tolidine, 3,3'5,5;-tetraalkylbenzidine wherein the alkyl groups contain from one to six carbon atoms; 9-dianisidine; 2,7-diaminofluorene; bis-(N-ethyl-quinol-2-one)-azine; (N-methylbenzthiazol-2-one)~ ethyl-3-phenyl-5-methyl-triazol-2-one)-azine or a combination thereof. Useful hydrop-eroxides include cumene hydroperoxide; 5-butyl hydroperoxide;
diisopropylbenzene hydroperoxide; 1-hydroxycyclohexane-1-hydroperoxide; 2,5-dimethyl-hexane-2,5-dihydroperoxide; para-menthane hydroperoxide; 1,4-diisopropylbenzene hydroperoxide;
p-5-butyl-isopropylbenzene hydroperoxide; 2-(a-hydroperoxy-isopropyl)-6-isopropylnaphthalene; tetralin hydro-peroxide or a combination thereof.
In U.S. Patent 4,493,890 it is disclosed that glucose oxidase is a conjugated enzyme composed of an enzymatically inactive, high molecular weight protein component (apoenzyme) and FAD (a low molecular weight, nonproteinaceous prosthetic group). Unlike transition metal porpyhrins, the flavin ade-nine dinucleotide (FAD) portion of glucose oxidase does not contain a transition metal. The FAD moiety is sometimes re-ferred to as a prosthetic group because the protein portion of the enzyme forms a complex with this small ligand through high affinity binding. As a result, the prosthetic group becomes an integral part of the protein which is required for the en-zyme to function. Apoglucose oxidase and FAD have a high binding affinity (binding constant of about 101~ molar -1) but can be effectively separated by treatment with acidified ammo-nium sulfate. In U.S. Patent 4,238,565 there is described a specific binding assay wherein FAD is employed as a label and is monitored by its ability to combine with apoglucose oxidase to form active glucose oxidase. In a homogenous assay for de-termining an antigen in a liquid medium, a test sample of the liquid medium is combined with antibody to the antigen and a labeled conjugate comprising the antigen (or analog thereof) coupled to FAD so that antigen contained in the sample com-petes with antigen-FAD for binding with antibody. Apoglucose oxidase is also present and is capable of combining with anti-gen-FAD which is not associated with antibody to yield active glucose oxidase. However, since antibody bound antigen-FAD is not capable of such combination with apoglucose oxidase, the concentration of antigen in the test sample dictates the amount of measurable glucose oxidase which results from the recombination by known methods such as a colorimetric assay.
This sort of assay, sometimes referred to as apoenzyme reacti-vation immunoassay system (ARIS) involves attachment of hapten to the FAD prosthetic group of glucose oxidase which still permits reactivation of the apoglucose oxidase by its interac-tion with the prosthetic group. However, binding of the anti-hapten antibody to the hapten-FAD conjugate can prevent its association with the apo-glucose oxidase, so that no glucose oxidase activity is observed. Glucose oxidase has been found to be an excellent enzyme for this system since i) the FAD can be dissociated from the intact enzyme to provide a stable apo-glucose oxidase, ii) the apoglucose oxidase cannot express en-zyme activity but can be easily reconstituted with FAD to the holoenzyme and iii) the parent holoenzyme has a high turnover rate and the H202 reaction product can be determined with high sensitivity by a variety of methods. However, the apoglucose oxidase ARIS method has not been successfully applied in uri-nalysis due to the presence of FAD derivatives in urine re-sulting in reconstitution with the apoglucose oxidase to form the active enzyme which can cause false positive assay re-sults. The ARIS systems are not limited by molecular weight .
of the prosthetic-conjugate:binding partner, i.e. reconstitu-tion occurs regardless of the molecular weight of the binding system. This type of assay is based on binding partner inter-action with the prosthetic-conjugate occurring in such an ori-entation that it causes steric hindrance to reconstitution.
This steric hindrance leads to an inhibition that causes the rates of reconstitution to be different between prosthetic conjugate and prosthetic-conjugate binding partner. The dif-ference in reconstitution rates of the two species is used to measure the analyte. Peroxidases also contain a prosthetic group in the form of a transition metal porphyrin which can be separated from the protein to form an apo-peroxidase. The apo-peroxidase system of the present invention is limited by the molecular weight of the analyte/analyte specific binding partner conjugate attached to the metal porphyrin since it was discovered that when this moiety has a total molecular weight of greater than that which will permit the apo-peroxidase and metal porphyrin to recombine, reconstitution with the peroxi-dase is prevented. Conjugates with a combined molecular weight of greater than about 180 K Dalton have been found to be suitable for preventing reconstitution. The present assay is based on the binding partner:prosthetic conjugate being so large that it prevents reconstitution. Since the binding partner typically has a high molecular weight (antibodies are normally in the 165 K Dalton range) the presence of peroxidase activity can only result from one species, the unbound pros-thetic-conjugate, and the activity of this single species is used to measure the analyte.
Steric hindrance to reconstitution requires a specific orientation of the antibody:antigen binding, which orientation is easily developed for small antigens but not for large anti-gens. Accordingly, the ARIS method is normally limited to small molecular weight antigens of 100 to 1000 g/mol. The present method does not rely on steric hindrance but rather on the molecular weight of the prosthetic-conjugate: binding partner. This technique results in the advantage that the as-say is able to detect any size of analyte and eliminates the need to prepare antibodies with a specific binding orienta-tion. Additionally, the present invention, which is based upon the discovery that the size effect can be used to provide an apo-peroxidase system, can be used without measuring rates.
This is especially advantageous in urinalysis using test strips since urine strips are usually read visually and visual readings are not readily applicable to rate determination.
The pseudoperoxidases also have prosthetic groups which, when removed, result in an inactive apo- form of the pseudop-eroxidase which lacks the peroxidase activity. For example, when iron hematin is separated from hemoglobin, such as by subjecting the hemoglobin to low pH to dissociate the iron hematin followed by filtration to cause the separation of the hematin and apo-hemoglobin, there is provided an inactive form of hemoglobin which may be reactivated by facilitating the re-constitution of the apo-hemoglobin and the iron hematin. The transition metals which constitute part of the metal porhyhrin will have a mixture of valences in reagents of the type under consideration.
In Abstracts of the Histochemical Society (1979), Item 39 on page 717 there is discussed an immunoassay using the degree of reconstitution of apoenzymes with active groups in the presence or absence of immuno complexes such as heme-labeled antigen when complexed with antibody will be inhibited from reconstituting with apoperoxidase.
Japanese published patent application 8-224095 discloses an assay system for Cu in which Cu is added to apogalactose oxidase in the presence of D-galactose and ~2 to produce H2O2 which reacts with an oxidative condensing agent in the pres-ence of peroxidase to produce a quinoid dye which colorimetri-cally measures the copper concentration in the fluid sample being tested.
While the use of the heme moiety as a label for apo-peroxidase was theorized by P. K. Nakanein, Univ. of Colo., Abstracts of the Histochemical Society, 39 (1979) where it was suggested that conjugated hematin-antigen would not readily intercalcate into apo-peroxidase when the antigen was bound to its corresponding antibody, an assay for analytes in fluid test samples employing this principle was never reduced to practice.
Summary of the Invention The present invention is an assay for an analyte in a fluid test sample which assay involves combining the fluid test sample with a hydroperoxide, a redox dye, an apo-peroxidase [or pseudo apo-peroxidase] and its corresponding metal porpyhrin which is bound to an analyte/analyte specific binding partner conjugate which conjugate has a total molecu-lar weight which is sufficiently high to prevent the porpyhrin component thereof from recombining with the apo-peroxidase.
, In this form the apo-peroxidase cannot interact with the hy-droperoxide to cause a colored response in the redox dye.
However, in the presence of analyte, there is interaction be-tween the analyte and the analyte specific binding partner which disrupts the analyte/analyte specific binding partner conjugate and thereby reduces the molecular weight of the moi-ety bound to the metal porpyhrin to less than that level at which the reconstitution of the apo-peroxidase and its pros-thetic group is inhibited. This allows the apo-peroxidase and the metal propyhrin to reconstitute to form an active peroxi-dase which can interact with the hydroperoxide and the redox dye to provide a colored response, the intensity of which is directly proportional to the concentration of analyte in the fluid test sample.
The assay of this invention can be used qualitatively or, with the use of appropriate calibration, colorimetric dyes and instrumentation to provide accuracy and precision, semi-quantitative results can be obtained.
Description of the Invention Metal-porpyhrins are the active center of peroxidatively active proteins and their removal such as by acidification and separation by either ultrafiltration or chromatography results in the formation of apo-peroxidases which have no peroxidase activity but which can be reactivated when mixed with metal-porphrins, even those which are conjugated to antigens. How-ever, antibody binding to these antigen/metal-porphyrin conju-gates prevents reactivation of the apo-peroxidase when this combination exceeds about 180 K Daltons in molecular weight.
Free antigen (analyte) in a fluid test sample, to which the antibody bound to the antigen of the antigen/metal porphyrin conjugate has been added, competes for antibody binding thereby freeing the antigen/metal porpyhrin conjugate from the antibody in proportion to the analyte present in the fluid test sample. In the case of antigen/metal porpyhrin conju-gates having a total molecular weight of less than about 180 K
Daltons, the antibody free conjugate reactivates the apo-peroxidase to the active form. The activity of the reacti-vated peroxidase can be detected using a redox indicator and a hydroperoxide at a pH of from 1 to 12 and preferably from 6.5 to 8.5. In this embodiment of the invention, there is pro-vided a test composition comprising:
i) a redox indicator and a peroxide as well as a buffer to maintain the pH at the optimal value, depending upon the metal and redox indicator used, of from 1 to 12;
ii) the specific binding partner (analyte or binding partner therefor)/metal-porpyhrin conjugate;
iii) the peroxidatively active substance lacking a pros-thetic heme group, i.e. apo-peroxidase; and iv) conjugate binding compounds.
The conjugate binder can take one of two forms:
a) if an antibody is bound to the metal porpyhrin, the binder is the antigen or the antigen bound to a larger molecule such as a protein, or b) if an antigen is bound to the conjugate, the binder can be an antibody or an antibody connected to a larger molecule or other biomolecules that bind the antigen can be used. For example, when LPS is the antigen, high density lipoprotein (HDL), which binds LPS, can be used. In the case where IgG is the ana-lyte, the binding partner can be complement factor protein.
Exemplary of antigen/metal-porpyhrin conjugates are met-als such as Fe, Mn, Cu and Co; porphyrins such as hematin, deteroporphyrin and coproporhrin and antigens such as pro-teins, low molecular weight organics and cell wall components.
Examples of apo-peroxidases and pseudoperoxidases which may be used in the present invention are apo-peroxidase, apo-hemoglobin, apo-myoglobin, apo-cyochrome-C, apo-catalyase and apo-lactoperoxidase.
This invention involves a dry reagent involving a new colorimetric technology based on a competitive apo-peroxidase chemistry which is useful for measuring small and large mo-lecular weight components in biological fluids such as blood and urine. Typical analytes involve drugs, proteins and cells, i.e. gram positive and gram negative bacterial cells.
The invention is based on the discovery that metal-porpyhrin conjugates will not intercalcate into apo-peroxidases when bound by a conjugate binder as long as the conjugate:binder complex has a molecular weight of greater than about 180,000 g/mol. It was found that conjugation of compounds up to a mo-lecular weight of an antibody (160,000 g/mol) did not inter-fere with apo-peroxidase reactivation, so that the conju-gate:binder complex can be an antigen:antibody complex wherein the antigen is the analyte whose presence or concentration is being sought and the antibody is a specific binding partner for the analyte. Specific binding partners other than anti-bodies include avidin/biotin pairs. The metal porpyhrin con-jugate can, for example, be comprised of an antibody and metal hematin wherein the conjugate binder (ligand) would be an an-tigen which is the analyte or derivative thereof recognized by the antibody and the analyte is the antigen recognized by the antibody. When the antibody antigen combination has a com-bined molecular weight of greater than about 180 K daltons it cannot intercalcate with the apo-peroxidase and a peroxidase catalyzed reaction does not result. However, when the conju-gate, conjugate binder, apo-peroxidase and a hydroperoxide are combined with a fluid test sample containing analyte, there takes place a competitive reaction in which analyte in the sample competes for binding with the antibody bound to antigen on the conjugate, and, to the extent that this competition strips antibody from the conjugate, thereby lowering its mo-lecular weight to below about 180 K Daltons, the conjugate can combine with the apo-peroxidase to provide an active enzyme which will catalyze the reaction needed to provide the detect-able response. The magnitude of this response will be propor-tional to the concentration of analyte in the test fluid which concentration can be determined by comparison with calibration charts prepared using known concentrations of analyte. A
similar response will be observed when the metal porhyhrin is conjugated with an antibody specific for the antigen (analyte) and the binder is the analyte or analyte derivative.
The method of practicing the present invention is further illustrated by the following procedures and examples.
A. Procedure for Preparing Reagent Used in Examples IV to VII.
Dry reagent paper was prepared through sequential impreg-nations of Whatman 3MM with an aqueous first dip and an etha-nol second dip using dryer temperatures of 100~C for 7 min-utes. The first dip contained buffer while the second dip contained the redox indicator, TMB, and the hydroperoxide, DBDH.
The first dip consisted of 10 mL of 73 mg/dL hematin-IgG, 1.0 mL of 10 mg/mL mouse anti-human kappa chain monoclonal an-tibody, 0.66 g glycerol-2-phos-phate, 4.2 ~M apo-hemoglobin, 0.63 g 4-morpholine propane sulfonic acid (MOPS) as buffer and 0.11 g of sodium dodecyl sulfate (SDS) as surfactant. The pH
was adjusted to 7.5 with IN NaOH.
The second dip contained 2.5 g of polyvinylpyrolidone, 1.6 g DBDH and 0.795 g TMB in 100 mL ethanol.
The preferred concentration and allowable range of each dip component are set out in Table 1:
APO-PEROXIDASE REAGENT
Preferred Allowable Concentration Range First Dip (aqueous) Glycerol-2-Phosphate225 nM 0-800 mM
MOPS 225 mM 0-800 mM
SDS 28 mM 8-100 mM
Fe-HEDTA (ascorbate 7.5 mM 0-20 mM
scavenger) Triisopropylamine borate 33 0-120 (stabilizer) Fe Hematin-antigen (metal 3.2 ~M 1-20 ~M
porpyhrin conjugate) Ab (competitive binder) 4.4 ~M 1-20 ~M
Apo-hemoglobin (Apo-peroxidase) 4.2 ~M 1-20 ~M
Adjust pH with 1 N NaOH 7.5 1-12 Second Dip (ethanol) Polyvinylpyrrolidone 2.5 w% 0-7.5 w%
Tetramethylbenzidine (TMB) 33 mM 5-100 mM
Diisopropyl benzene dihydroperoxide (DBDH) 66 mM 5-150 mM
Orange G dye (Background dye) 0.20 mM 0-5 mM
Ethyl Orange dye (Background 0.20 mM 0-5 mM
dye) B. The reagent papers produced from the above dips were cut into strips and dipped into urine containing various hematins from a urine pool of 1.015 specific gravity. The reflectance at 660 nm, measured using a CLINITEK -200+ instrument, ob-tained one minute after dipping, was taken as representative of reagent activity.
Example I - Detection Limit Study In this example apo-peroxidase is compared to hematin and hematin-antigen conjugates to determine the detectable concen-trations and effects of conjugation and antigen molecular weight on apo-enzyme reactivations. Solutions containing com-binations of apo-POD, Fe 3 hematin and hematin conjugate were tested for peroxidase activity. Peroxidase activity was meas-ured in urine using HEMASTIX~ reagent as set out in Table 3.
This reagent is similar to that set out in Table 1 but lacking the metal porphyrin conjugate, competitive binder and apo-peroxidase while containing lepidine as an activator. The re-sults of this detection limit study are set out in Table 2.
Mean ~ Reflectance @ 660 nm (1 minute @ 30~ C) Case Composition Conc: 3.6 mM 3.6 nM 3.6 nM
A hematin 65.1 64.9 63.4 C apo-POD, hematin 55.3 46.3 48.9 E apo-POD 64.1 62.3 61.2 antigen: 8JP IgG Sulf-methazine M~l~rlll~r Wt. 23,000 160,000 278 P Antigen-hematin 65.8 67.0 64.5 D apo-POD, antigen-hematin 49.1 39.9 42.3 The peroxidase activity of hematin (Case A) or antigen hematin conjugate (Case B) was not detectable at a concentra-tion of 3.6 nM. The apo-POD also demonstrated no activity by itself (Case E) whereas the peroxidase activity of hematin (Case C) and antigen-hematin conjugate (Case D) was detectable at 3.6 nM in the presence of apo-POD. This example demon-strates that detection of nM quantities via peroxidase reacti-vation is possible with the redox indicator and hydroperoxide technology which has a turn over rate of 10 moles of DBDH/min and a dye (TMB) molar extinction of 10 . Conjugation of the hematin with antigen did not interfere with the apo-enzyme re-activation. In fact, in the antigen hematin conjugates of Case D, the reactivation caused a response as great as 25.0%R
at 1 minute, as can be determined by comparing 3.6 nM apo-peroxidase (Case E) to 3.6 nM apo-peroxidase:antigen-hematin (Case D). Surprisingly, conjugation of antigens up to a mo-lecular weight of 160,000 g/mol (in the case of IgG) did not prevent reactivation of the apo-POD. Reactivation was com-plete in 1 minute (demonstrating the short equilibrium times) and was not dependent upon temperatures from 20-40~C or apo-POD concentration.
Procedure for Detection Limit Experiment A 10 ~L portion of hematin (3.6 ~M, 0.23 mg/dL in phos-phate buffered saline) or a 10 ~L hematin-BJP allotment (3.6 ~M, 8.61 mg/dL in phosphate buffered saline) was mixed with 10 ~L apo-POD (3.6 ~M, 14.0 mg/dL in phosphate buffered saline) all in 980 ~L of phosphate buffered saline and then diluted to the desired concentration with additional phosphate buffered saline. The solution was incubated for 1 minute at 40~C or at room temperature. The response of HEMASTIX~ reagent dipped into the test solution was measured on a CLINITEK -200 reflec-tance instrument. The response of the reagent set out in Ta-ble 1 on the phosphate buffered solution alone was 65.2% re-flectance at 1 minute.
Apo-horse radish peroxidase was obtained from Sigma Chemical Company of St. Louis, MO. The phosphate buffered so-lution was prepared by adding 0.69 g monobasic sodium phos-phate, 0.71 g of dibasic sodium phosphate and 0.45 g of sodium chloride to 100 mL of water.
Procedure for Antigen Response Experiment A 10 ~L sample of hematin-BJP (3.6 ~M, 8.61 mg/dL in phosphate buffered saline), anti-BJP (3.6 ~M, 52.56 mg/dL in PBS) and BJP (3.6 ~M, 8.28 mg/dL in phosphate buffered saline) were mixed with 10 ~L apo-POD (3.6 ~M, 14.0 mg/dL in phosphate buffered saline) and 960 L phosphate buffered saline. The so-lution was incubated for 5 to 10 minutes at room temperature and the response to HEMASTIX~ reagent dipped in the test solu-tion was measured using a CLINITEK~-200 instrument. The re-sponse of HEMASTIX~ reagent with the phosphate buffered saline solution containing hematin alone was 65.7% reflectance at 1 minute. Sheep anti-human BJP monoclonal antibody was obtained from The Binding Site Limited of Birmingham, England.
The HEMASTIX~ reagent referred to earlier with the addi-tion of lepidine and at a lower pH when compared to the for-mula of Table 1 was applied to the strip in a two dip system of the following composition and used in Examples I to IV.
BJP = Bence Jones Protein CA 02249778 l998-l0-08 Allowable First Dip (Aqueous)Concentration Range Glycerol-2-Phosphate225 mM 0-800 mM
MOP 225 mM 0-800 mM
SDS 28 mM 8-100 mM
Triisopropylamine borate 33 mM 0-120 mM
Fe-HEDTA 7.5 mM 0-20 mM
Adjust pH with 1 N NaOH 6.3 5.5-8.5 Second Dip (Ethanol) Polyvinylpyrrolidone2.5 w% 0-7.5 w%
Tetramethylbenzidine [TMB] 33 mM 5-100 mM
Diisopropyl Benzene Dyhydroperoxide [DBDH] 66 mM 5-150 mM
Lepidine 100 mM 5-150 mM
Orange G dye (background dye) 0.20 mM 0-5 mM
Ethyl Orange dye (background dye) 0.20 mM 0-5 mM
Example II - Proximity Effect In this example, antibody binding of the hematin-antigen conjugate is shown to prevent apo-enzyme reactivation (Table 3). The data set out in Table 3 were generated by using the HEMASTIX~ formula with lepidine but lacking apo-peroxidase, antigen-hematin antigen and antibody. The later were mixed in solution and reagent strips with the modified HEMASTIX~ for-mula were immediately dipped into the solution and read using a CLINITEKTM-200+ reflectance spectrometer.
The prevention of apo-enzyme reactivation was observed as long as the [hematin] antigen/antibody complex had a molecular weight of greater than 180,000 g/mol. Accordingly, sul-famethazine plus antibody (mol wt. # 161,000) did not prevent apo-enzyme reactivation. However, attachment of sulfmethazine to polyacrylic acid (PAA) (mw = 200,000 g/mol) did prevent re-activation of the apo-enzyme as shown by 51.5%R observed for run 10. It was also shown that an antigen (IgG-mol. wt.
160,000 and BJP-mol. wt. 23,000) could be detected in urine by its ability to free hematin-antigen[antibody] conjugate to re-activate apo-POD by breaking the binding between antigen and antibody.
APO- Antigen- Roagent Response (%R
Run Antigen Peroxidase Hematin [Antigen] Antibody @ 30 Sec) @ 660 nm 1 BJP 36 nM 36 nM None 36 nM 43.1 2 aJP 36 nM 36 nM 12 nM 36 nM 33.7 3 ~3JP 36 nM 36 nM 24 nM 36 nM 26.6 4 aJP None 36 nM 36 nM 36 nM 41.7 PJP 36 nM 36 nM None None 24.2 6 IgG 36 nM 36 nM None 36 nM 42.4 7 IgG 36 nM 36 nM 24 nM 36 nM 19.2 a Sulfamethazine 36 nM 36 nM None 36 nM 23.6 9 Sulfamethazine 36 nM 36 nM 24 nM 36 nM 21.3 Sulfmethezine 36 nM 36 nM None 36 nM 51.5 PAA
11 Sulfmethazine 36 nM 36 nM 24 nM 36 nM 49.2 PAA
Example III - Interference Study In this example, a peroxidase detecting dry reagent with resistance to 0.81 mg/dL hemoglobin (or myoglobin) and 25 mg/dL ascorbate and sufficient sensitivity to detect apo-peroxidase reactivation was used. The peroxidase detecting reagent was made by removing lepidine activator in the HE-MASTIX~ reagent and increasing the pH to 7.5. Without modifi-cation, hemoglobin (or myoglobin) causes a false positive re-sponse. Ascorbate does not cause a false negative response in the system due to the use of an ascorbate scavenger system.
The reagent was tested by dipping it into solutions con-taining the interfering substance with and without Fe hematin.
These formulation changes to the HEMASTIX~ reagent also re-duced the sensitivity of the reagent needed to detect apo-peroxidase reactivation from 3 nM in Example I to 12 yM in this Example III. As expected, the 12 yM hematin was acti-vated by the addition of 12 yM apo-POD. The results of this interference study are set out in the following Table 5.
0.81 mg/dL 0.81 mg/dL 25 mg/dL
Reagent Water Mb Hb Ascorbic Mean SD Mean SD Mean SD Mean SD
~IRMA!::'I'TY~
(lepidine/pH 6.3) 63.6 3.1 5.1 2.7 3.0 0.4 66.4 4.5 + 3.6 ~M Fe Hematin 8.8 1.9 + 12 ~M Fe Hematin 6.4 1.0 5.3 0.6 + 12 ~M Fe Hematin/ 4.1 0.4 12 ~M apo-POD
+ 36 ~M Fe Hematin 3.1 1.4 HEMAS~IX~
(no lepidine/pH 7.5) 77.4 1.7 78.2 1.6 76.5 1.2 79.4 2.3 + 3.6 ~M Fe Hematin 79.2 1.3 + 12 ~M Fe Hematin 72.4 3.0 73.2 3.1 + 12 ~M Fe Hematin/
12 ~M apo-POD 54.0 5.7 55.3 3.4 From Table 5 one can determine that HEMASTIX~ with lepidine is interfered with by hemoglobin or myoglobin as shown by 5.1%
and 3.0% responses verses 78.2 and 76.5.
Example IV - Metal Porphyrin Study:
In this example, other metal porphyrins were tested for their ability to reactivate different types of apo-peroxidases. Metals such as Fe, Cu, Mg, Zn, Ni, Mn, Co and Pd were complexed to hematin and added to the peroxidase detect-ing agent. Metals such as Mn, Fe, Cu and Co and porphyrins other than hematin, i.e. deteroporhyrin and coproporphyrin . .
were also shown to provide the desired response. This is il-lustrated in Table 6 by the combination of apo-peroxidase with iron and manganese porphyrin resulted in color formation (lower % R) as compared to water. An apo-pseudo-peroxidase, apo-hemoglobin, was shown to work in this experiment.
~R @ 90 ~econd read time on CLINITEK -200+
Water 12 ~M apo-POD 12 ~M apo-Hb Reagent Mean SD Mean SD Mean SD
HEMASTIX~ (no lepitine/pH 7.5)Column 1 Column 2 Column 3 + 12 ~M Fe Hematin 71.5 1.9 50.9 4.2 45.3 1.2 + 12 ~M Fe .u~Lu~uL~l.yLln 69.7 1.1 56.4 3.6 52.1 3.5 + 12 ~M Fe deteroporphyrin 72.2 3.1 56.1 5.2 49.2 2.3 + 120 ~M Mn deterophpyrin 66.4 3.2 48.2 4.3 -~
+ 120 ~M Co deteroporphyrin 71.5 2.2 74.1 1.4 ---- ----+ 120 ~M Mg deteroporphyrin 74.4 1.3 70.9 2.9 ---- ----+ 120 ~M Pb deteroporphyrin 72.1 1.9 73.4 1.9 ---- ----+ 120 ~M Ni deteroporphyrin 75.5 2.4 76.1 2.1 ---- ----+ 120 ~M Zn det~L U~UL ~ly L in 71.3 1.5 70.7 1.8 ---- ----+ 120 ~M Cu deterporphyrin 73.7 3.9 57.2 1.2 ---- ----The data of Table 6 demonstrate that no metal porphyrin is detected without apo-peroxidase or apo-hemoglobin as shown by the percent reflectance in Column 1 being 2 66%R. The ad-dition of either apo-peroxidase or apo-hemoglobin causes a colored response as shown by %R of ~ 56 in Columns 1 and 3.
The response is similar for three different porphryins. The use of Mn and Cu resulted in responses similar to those ob-tained for Fe as shown in Column 2. The other metals were not active in this system since the activity of the metal is de-pendent on the particular peroxide, pH and redox indicator used.
Example V - Complete Dry Reagent - for IgG
In this example, the ascorbate and hemoglobin resistant reagent for detecting peroxidase reactivity was combined with apo-hemoglobin; Fe hematin conjugated to human IgG and anti-human IgG into one reagent (Table 1). As demonstrated by Ta-ble 7, the complete reagent detected IgG in urine with good correlation between the concentration of IgG in the test solu-tion and the response recorded.
96R @ 90 sec read time on CLINITEK -200+
Reagent 0 ~M 12 IIM 24 ,uM 36 ~IM
IgG IgG IgG IgG
Mean SD Mean SD Mean SD Mean SD
Apo-peroxidase 61.2 3.5 55.3 1.2 49.5 3.4 42.3 4.6 Reagent contained 12 IIM Fe Elematin-IgG, 12 ,uM anti IgG and 12 IIM apo-l ~lnh1n Example VI - Complete Dry Reagent for Gram Negative Cells In this example, the ascorbate and hemoglobin resistant reagent for detecting peroxidase activity was combined with apo-hemoglobin; Fe hematin conjugated and an antibody specific to an anti-rabbit bacterial lipopolysaccharide (LPS) into one reagent. The Fe-hematin-LPS conjugate was made up of 16.3 LPS
molecules attached to oval albumin along with 5. 2 hematin molecules. As demonstrated by Table 8, the complete reagent detected bacterial cells in urine with three species of gram negative cells being detected. Since all gram negative cells have LPS on their surfaces, this technique provides a screen for gram negative urinary tract infections. A specimen con-taining gram negative cells would disrupt the binding of the LPS conjugate to antibody as the LPS of the gram negative cells binds to the antibody. The LPS conjugate is then free to reconstitute with apo-hemoglobin to form its active form to generate a detectable response.
96 R @ 650 nm and 90 Sec Road Time on CLINITEK 200+
Organism ~ 103 105 107 cells/ul Proteus mirabilis (ATCC 25933) 65.0 58.7 44.8 P ' -~ aeruginosa (ATCC 9027) 71.5 53.3 48.5 38.2 E coli (ATCC 8739) 66.0 60.2 49.9 The antibody was rabbit anti-E. coli LPS; catalog #YBDB30506R: Lot #G4520; neat antisera; Accurate Chemical &
Scientific Corporation of Westbury, NY.
The following experimental methods were used in the fore-going examples:
Procedure for Preparation of Conjugate A 868 ~M solution of hematin in 0.1 N NaOH (55 mg/dL, 633.51 g/mol) was added to a 858 ~M solution of 1,3-dicyclohexyl carbodiimide in acetonitrile (19.4 mg/dL, 226 g/mol) and stirred for five minutes at room temperature. A
solution containing 25 yM of the activated hematin and 12 ~M
antigen (either human kappa Bence Jones Protein (BJP) at 30 mg/dL or human gamma globulin (IgG) at 200 mg/dL) was made and stirred for an additional five minutes at room temperature.
The hematin-antigen conjugate was separated from the free an-tigen by centrifugation to dryness using an Amicon Ultra fil-tration membrane followed by several washings with deionized water. Hematin conjugate is more reluctant to pass through the membranes than IgG or BJP resulting in the conjugate being collected on the membrane. After the final washing, the hematin-antigen conjugate was dissolved in 175 mL of deionized ., water. The reaction was found to be greater than 64% complete by protein determination using the coomassie brilliant blue method and contained 128 mg of protein/4.3 ~M conjugate.
The coomassie brilliant blue method was performed by add-ing 30 ~L of sample to 1.5 mL of Bradford reagent (0.01 g coomassie brilliant blue, 10 mL 85% phosphoric acid, 5 mL
ethanol and 85 mL water) and measuring absorbance at 590 nm and comparing the absorbance to a standard curve of protein concentration.
Procedure for making apo-hemoqlobin A 0.7% solution of hemoglobin was lowered to pH 1.5 and the resulting solution was ultrafiltered through a 10 KDa cut-off membrane followed by several changes of water. Filtered material was reconstituted into water. The apo-hemoglobin passed through the filter while the dark Fe hematin and hemo-globin remained behind. The filtrate, 440 mL of which was collected, was found to contain 430 mg of protein (apo-hemoglobin) by assay or 23 ~M. The HEMASTIX~ result was + for this solution indicating that the amount of hemoglobin was low. The collected fraction which did not pass through the filter was dissolved in 75 mL of water and was found to con-tain 270 mg of protein by assay. It produced a HEMASTIX~ re-sult of +++++ indicating a high concentration of hemoglobin.
Claims (20)
1. An assay for an analyte in a fluid test sample which comprises combining the fluid test sample with a hydroperoxide and a redox dye, together with an apo-peroxidase or apo-pseudoperoxidase and a metal porpyhrin which is bound to an analyte/analyte specific binding partner conjugate, said conjugate having a combined molecular weight which is sufficiently high to prevent reconstitution of the apo-peroxidase or apo-pseudoperoxidase and metal porpyhrin in the absence of analyte but allow such reconstitution in the presence of analyte in the fluid test sample due to interaction between the analyte in the fluid test sample and the analyte specific binding partner portion of the conjugate which disrupts the conjugate to thereby reduce the molecular weight of the moiety bound to the metal porpyhrin to less than that level at which the reconstitution of the apo-peroxidase and metal porpyhrin is inhibited so that the apo-peroxidase and its corresponding metal porpyhrin can reconstitute to form an active peroxidase which will interact with the hydroperoxide and the redox dye at a pH of from about 1 to 12 to provide a colored response.
2. The assay of Claim 1 wherein the analyte/analyte specific binding partner conjugate has a molecular weight of at least about 180 K Daltons.
3. The assay of Claim 1 wherein the analyte/analyte specific binding partner conjugate is bound to the metal porpyhrin through the analyte specific binding partner.
4. The assay of Claim 1 wherein the analyte specific binding partner is an antibody or a fragment thereof.
5. The assay of Claim 1 wherein the analyte/analyte specific binding partner conjugate is bound to the metal propyhrin through the analyte.
6. The assay of Claim 4 wherein the analyte is a bacterial cell or a portion thereof.
7. The assay of Claim 6 wherein the bacterial cell portions are lipopolysaccharide (LPS) or lipoteichoic acid (LPA).
8. The assay of Claim 1 wherein the hydroperoxide is cumene hydroperoxide; 5-butyl hydroperoxide; diisopropylbenzene hydroperoxide; 1-hydroxycyclohexane-1-hydroperoxide;
2,5-dimethylhexane-2,5-dihydroperoxide; paramenthane hydroperoxide;
1,4-diisopropylbenzene hydroperoxide; p-t-butyl-isopropylbenzene hydroperoxide; 2-(.alpha.-hydroperoxyisoporopyl)-6-isopropylnaphthalene; tetralin hydroperoxide or a combination thereof.
2,5-dimethylhexane-2,5-dihydroperoxide; paramenthane hydroperoxide;
1,4-diisopropylbenzene hydroperoxide; p-t-butyl-isopropylbenzene hydroperoxide; 2-(.alpha.-hydroperoxyisoporopyl)-6-isopropylnaphthalene; tetralin hydroperoxide or a combination thereof.
9. The method of Claim 1 wherein the dye is benzidine;
o-tolidine, 3,3',5,5'-tetraalkylbenzidine wherein the alkyl groups contain from one to six carbon atoms; 9-dianisidine;
2,7-diaminofluorene; bis-(N-ethylquinol-2-one)-azine;
(N-methylbenzthiazol-2-one)-(1-ethyl-3-phenyl-5-methyltriazol-2-one)-azine or a combination thereof.
o-tolidine, 3,3',5,5'-tetraalkylbenzidine wherein the alkyl groups contain from one to six carbon atoms; 9-dianisidine;
2,7-diaminofluorene; bis-(N-ethylquinol-2-one)-azine;
(N-methylbenzthiazol-2-one)-(1-ethyl-3-phenyl-5-methyltriazol-2-one)-azine or a combination thereof.
10. An assay for an analyte in a fluid test sample comprising combining the fluid test sample with a reagent system comprising a hydroperoxide, a redox dye and a redox dye together with an apo-peroxidase and a metal porphrin bound to an analyte/analyte specific binding partner conjugate which analyte/analyte specific binding partner conjugate has a molecular weight of at least about 180 K Daltons to cause the apo-peroxidase and metal porphyrin to recombine to form an active peroxidase in the presence of analyte in the fluid test sample so that it can interact with the hydroperoxide and redox dye to provide a colored response.
11. A test kit for the determination of an analyte in a fluid test sample, which test kit comprises:
i) a redox indicator and a peroxide as well as a buffer to maintain the pH of the fluid test sample at a level of from 1 to 12 when the buffer and fluid test sample are combined;
ii) an analyte or analyte specific binding partner/metal-porpyhrin conjugate;
iii) a peroxidatively active substance lacking a prosthetic heme group; and iv) a conjugate binding compound.
i) a redox indicator and a peroxide as well as a buffer to maintain the pH of the fluid test sample at a level of from 1 to 12 when the buffer and fluid test sample are combined;
ii) an analyte or analyte specific binding partner/metal-porpyhrin conjugate;
iii) a peroxidatively active substance lacking a prosthetic heme group; and iv) a conjugate binding compound.
12. The test kit of Claim 11 wherein an analyte specific binding partner is bound to the metal-porpyhrin and the conjugate binding compound is the analyte, an analog of the analyte or the analyte bound to a larger molecule.
13. The test kit of Claim 11 wherein the analyte or an analog thereof is bound to the metal-porpyhrin and the conjugate binding compound is a specific binding partner for the analyte.
14. An assay for the presence of bacteria cells characterized by having lipopolysaccharide (LPS) or lipoteichoic acid (LPA) on the cell surface in a fluid test sample which assay comprises combining the fluid test sample with a hydroperoxide and a redux dye, together with an apo-peroxidase or apo-pseudoperoxidase and a metal porpyhrin which is bound to a conjugate of anti-high density lipoprotein (HDL) and HDL which conjugate prevents reconstitution of the apo-peroxidase or apo-pseudoperoxidase and metal porpyhrin in the absence of the bacteria but allows such reconstitution in the presence of the bacteria in the fluid test sample due to interaction between the bacteria and the HDL which disrupts the conjugate which disruption allows the metal porpyhrin to reconstitute with the apo-peroxidase or apo-pseudopeoxidase to form an active peroxidase or pseudoperoxidase which can interact with the hydroperoxide and the redox dye at a pH of from 1 to 12 to provide a colored response which colored response is indicative of the presence of bacteria in the fluid test sample.
15. The assay of Claim 14 wherein the bacteria is gram negative having LPS on its cell surface.
16. The assay of Claim 15 wherein the fluid test sample is urine.
17. The assay of Claim 16 wherein the gram negative bacteria is Proteus mirabilis, Pseudomonas aeruginosa or E. coli.
18. The assay of Claim 14 wherein the bacteria is gram positive having LPS on its surface.
19. The assay of Claim 18 wherein the fluid test sample is urine.
20. An assay for the presence of IgG in a fluid test sample which assay comprises combining the fluid test sample with a hydroperoxide and a redox dye, together with an apo-peroxidase and a metal porpyhrin which is bound to a conjugate of anti-IgG and complement factor protein which conjugate prevents reconstitution of the apo-peroxidase and metal porpyhrin in the absence of IgG but allows such reconstitution in the presence of IgG in the fluid test sample due to interaction between the gram negative bacteria and the complement factor protein which disruption allows the metal porphyrin to reconstitute with the apo-peroxidase to form an active peroxidase which can interact with the hydroperoxide and the redox dye at a pH of from 1 to 12 to provide a colored response which colored response is indicative of the presence of IgG in the fluid test sample.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99038997A | 1997-12-15 | 1997-12-15 | |
| US08/990,389 | 1997-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2249778A1 true CA2249778A1 (en) | 1999-06-15 |
Family
ID=25536101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002249778A Abandoned CA2249778A1 (en) | 1997-12-15 | 1998-10-08 | Competitive apo-peroxidase assay |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6228602B1 (en) |
| EP (1) | EP0924521B1 (en) |
| JP (1) | JPH11237382A (en) |
| AU (1) | AU742373B2 (en) |
| CA (1) | CA2249778A1 (en) |
| DE (1) | DE69806567T2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074881A (en) * | 1998-08-03 | 2000-06-13 | Bayer Corporation | Method for the prevention of hemoglobin interference in reagent systems for measuring peroxidase activity |
| US6872573B2 (en) * | 2003-01-02 | 2005-03-29 | Bayer Corporation | Fluorescent creatinine assay |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US4238565A (en) * | 1978-06-22 | 1980-12-09 | Miles Laboratories, Inc. | Specific binding assay with a prosthetic group as a label component |
| US4376165A (en) * | 1978-06-22 | 1983-03-08 | Miles Laboratories, Inc. | Method of preparing an enzyme-labeled ligand for use in specific binding assays and the labeled conjugate produced thereby |
| JPS55111794A (en) * | 1979-02-19 | 1980-08-28 | Agency Of Ind Science & Technol | Production of lipid having high linolic acid content |
| US4340668A (en) * | 1979-06-04 | 1982-07-20 | Miles Laboratories, Inc. | Heme-labeled specific binding assay |
| US4792521A (en) * | 1985-08-15 | 1988-12-20 | Immunomedics, Inc. | Non-enzymatic immunohistochemical staining system and reagents |
| US5106753A (en) * | 1989-01-26 | 1992-04-21 | Miles Inc. | Method for determining manganese level in blood using a porphyrin composition |
| US5089420A (en) * | 1990-01-30 | 1992-02-18 | Miles Inc. | Composition, device and method of assaying for a peroxidatively active substance utilizing amine borate compounds |
| US5318894A (en) * | 1990-01-30 | 1994-06-07 | Miles Inc. | Composition, device and method of assaying for peroxidatively active substances |
| US5182213A (en) * | 1991-03-18 | 1993-01-26 | Miles Inc. | Method for detecting the presence of peroxidatively active substance in basic media |
| US5264348A (en) * | 1991-05-13 | 1993-11-23 | Miles Inc. | Ascorbate interference-resistant composition, device and method of assaying for predetermined analyte |
| DE69219686T2 (en) * | 1991-07-29 | 1997-09-11 | Mochida Pharm Co Ltd | Method and device for use in specific binding tests |
| US5173431A (en) * | 1991-10-12 | 1992-12-22 | Miles Inc. | Copper oxidation protein assay |
| US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US5374561A (en) * | 1993-10-25 | 1994-12-20 | Miles Inc. | Oxidative creatinine assay |
| US5733787A (en) * | 1996-06-17 | 1998-03-31 | Bayer Corporation | Method for the detection of creatinine |
-
1998
- 1998-10-08 CA CA002249778A patent/CA2249778A1/en not_active Abandoned
- 1998-12-02 EP EP98122881A patent/EP0924521B1/en not_active Expired - Lifetime
- 1998-12-02 DE DE69806567T patent/DE69806567T2/en not_active Expired - Fee Related
- 1998-12-11 AU AU97074/98A patent/AU742373B2/en not_active Ceased
- 1998-12-14 JP JP10354203A patent/JPH11237382A/en active Pending
-
1999
- 1999-10-12 US US09/415,491 patent/US6228602B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69806567T2 (en) | 2002-11-21 |
| JPH11237382A (en) | 1999-08-31 |
| DE69806567D1 (en) | 2002-08-22 |
| AU9707498A (en) | 1999-07-01 |
| EP0924521A1 (en) | 1999-06-23 |
| EP0924521B1 (en) | 2002-07-17 |
| US6228602B1 (en) | 2001-05-08 |
| AU742373B2 (en) | 2002-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5264348A (en) | Ascorbate interference-resistant composition, device and method of assaying for predetermined analyte | |
| JP2922003B2 (en) | Improved compositions, tools and methods for assaying for peroxide active substances | |
| US4361648A (en) | Color fixed chromogenic analytical element | |
| EP0123115B1 (en) | Ascorbate interference-resistant composition, device and method for the determination of peroxidatively active substances | |
| US8354245B2 (en) | Method of assaying glucose-6-phosphate dehydrogenase on a chromatographic test strip | |
| US5089420A (en) | Composition, device and method of assaying for a peroxidatively active substance utilizing amine borate compounds | |
| JPH06502244A (en) | Assay for glycanated blood proteins | |
| US5374561A (en) | Oxidative creatinine assay | |
| EP0814335B1 (en) | Method for the detection of creatinine | |
| US4713324A (en) | Inverted latency specific binding assay | |
| AU3598289A (en) | Visual discrimination qualitative enzyme assay | |
| GB1579040A (en) | Analytical compositions | |
| NO161287B (en) | HOMOGENIC IMMUNOLOGICAL METHOD OF ANALYSIS, REAGENTS AND TESTING DEVICES FOR USE BY IMMUNO ANALYSIS DETERMINATION. | |
| JPH10511776A (en) | Receptor: free ligand (Reland) complex and assays and kits based thereon | |
| JPH063447B2 (en) | Signal enhancement method for immunoassay by chemical catalyst modulator | |
| EP0306803B1 (en) | Test composition device and method for the visual determination of hydrogen peroxide | |
| EP0924521B1 (en) | Competitive apo-peroxidase assay | |
| JPH0595797A (en) | Analyzing method and device using peroxidase indicator for basic medium | |
| AU769431B2 (en) | Improved assay for the detection of creatinine | |
| EP0195320B1 (en) | Diagnostic assay using microperoxidase | |
| US5041658A (en) | Carboxamido nitrobenzene disulfide compound | |
| US20040248223A1 (en) | Reduction of interfering peroxidase activity in peroxidase based detection methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20041008 |